Meglus Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 2 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.84 Cr
About Meglus Pharmaceutical
Meglus Pharmaceutical Private Limited (MPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 27 April 2022 (Two years and ten months 0 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.84 Cr.
Rajeshkumar Patel and Surendrabhai Patel serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299GJ2022PTC131466
- Company No.
131466
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Apr 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Meglus Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeshkumar Patel  | Director | 26-Nov-2023 | Current |
| Surendrabhai Patel | Director | 27-Apr-2022 | Current |
Financial Performance of Meglus Pharmaceutical.
Enhance accessibility to Meglus Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Meglus Pharmaceutical?
Unlock access to Meglus Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹28.35 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.84 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Oct 2024 | Others | ₹1.35 M | Open |
| 01 Mar 2023 | Others | ₹1.10 Cr | Open |
| 12 Jan 2023 | Others | ₹1.60 Cr | Open |
How Many Employees Work at Meglus Pharmaceutical?
Meglus Pharmaceutical has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meglus Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meglus Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
